scispace - formally typeset
M

Michael Fiegl

Researcher at Ludwig Maximilian University of Munich

Publications -  111
Citations -  4814

Michael Fiegl is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Myeloid leukemia & Cancer. The author has an hindex of 31, co-authored 110 publications receiving 4276 citations. Previous affiliations of Michael Fiegl include University of Texas MD Anderson Cancer Center.

Papers
More filters
Journal ArticleDOI

Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction

TL;DR: It is demonstrated that pharmacologic inhibition of FAO with etomoxir or ranolazine inhibited proliferation and sensitized human leukemia cells to apoptosis induction by ABT-737, and evidence suggesting that FAO regulates the activity of Bak-dependent mitochondrial permeability transition is generated.
Journal ArticleDOI

Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy

TL;DR: It is concluded that a p53 gene deletion, which can be identified by interphase FISH in almost a third of patients with newly diagnosed MM, is a novel prognostic factor predicting for short survival of MM patients treated with conventional-dose chemotherapy.
Journal ArticleDOI

Mitochondrial uncoupling and the Warburg effect: Molecular basis for the reprogramming of cancer cell metabolism

TL;DR: Intriguingly, leukemia cells cultured on bone marrow-derived stromal feeder layers are more resistant to chemotherapy, increase the expression of uncoupling protein 2, and decrease the entry of pyruvate into the Krebs cycle-without compromising the consumption of oxygen, suggesting a shift to the oxidation of nonglucose carbon sources to maintain mitochondrial integrity and function.
Journal ArticleDOI

Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry.

TL;DR: The main achievement of the present work is the validated identification of compounds observed in exhaled breath of lung cancer patients, and this identification is indispensible for future work on the biochemical sources of these compounds and their metabolic pathways.